ERAS Stock Overview
A clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Erasca, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.92 |
| 52 Week High | US$3.45 |
| 52 Week Low | US$1.51 |
| Beta | 1.16 |
| 11 Month Change | 10.61% |
| 3 Month Change | 3.91% |
| 1 Year Change | 63.13% |
| 33 Year Change | -79.47% |
| 5 Year Change | n/a |
| Change since IPO | -83.25% |
Recent News & Updates
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Oct 15
Erasca: New Focus After Restructuring, But Need More Differentiation
Sep 30Recent updates
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Oct 15Erasca: New Focus After Restructuring, But Need More Differentiation
Sep 30Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?
Feb 21We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully
Nov 16Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth
Jun 28We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Jan 20Erasca forms clinical trial partnership with Pfizer for cancer therapy
Oct 20Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Sep 23Erasca adds 10% ahead of R&D Day
Sep 07Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers
Jul 18We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Dec 28Shareholder Returns
| ERAS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.6% | 4.3% | 1.6% |
| 1Y | 63.1% | 18.8% | 32.3% |
Return vs Industry: ERAS exceeded the US Biotechs industry which returned 18% over the past year.
Return vs Market: ERAS exceeded the US Market which returned 32.4% over the past year.
Price Volatility
| ERAS volatility | |
|---|---|
| ERAS Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ERAS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ERAS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 126 | Jonathan Lim | www.erasca.com |
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
Erasca, Inc. Fundamentals Summary
| ERAS fundamental statistics | |
|---|---|
| Market cap | US$785.98m |
| Earnings (TTM) | -US$159.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.2x
P/E RatioIs ERAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERAS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$159.12m |
| Earnings | -US$159.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ERAS perform over the long term?
See historical performance and comparison